Abstract
Drug repurposing has been proposed as a strategy to develop new therapies that has fewer risks, lower costs and shorter timelines than developing completely new drugs. However, the potential of this strategy has not been as widely realized as hoped, in part owing to legal and regulatory barriers. Here, we highlight these barriers and consider how they could be overcome.
References
Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683 (2004).
Grabowski, H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat. Rev. Drug Discov. 7, 479–488 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Breckenridge, A., Jacob, R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov 18, 1–2 (2019). https://doi.org/10.1038/nrd.2018.92
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.92
- Springer Nature Limited
This article is cited by
-
Drug repurposing for cancer therapy
Signal Transduction and Targeted Therapy (2024)
-
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
Applied Health Economics and Health Policy (2023)
-
Drug repurposing and new drug targets: perspectives for novel treatment options in mental health disorders
Journal of Neural Transmission (2023)
-
From GWAS to drug screening: repurposing antipsychotics for glioblastoma
Journal of Translational Medicine (2022)
-
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Nature Reviews Cardiology (2022)